The Parkinson's Progression Markers Initiative (PPMI)
The purpose of this research study is to collect clinical information, samples of blood, urine, spinal fluid, and brain images from 1) people with Parkinson Disease (PD), 2) people who may be at risk to develop PD
The information collected in this study will be used to help develop biomarkers for PD. Biomarkers are measures that may help us to understand how PD changes over time and may help us test drugs to treat the disease in the future.
1) Parkinson disease 2) Have a positive genetic mutation in the LRRK2, SNCA or GBA gene
This study is currently recruiting 1) people who know from prior genetic testing that they carry a "risk" gene for PD called LRRK2, GBA, or SNCA. 2) Healthy people with a family history of PD who have an Ashkenazi Jewish or Italian heritage 3) Healthy people with a family history of the LRRK2, GBA, or SNCA gene mutation. 4) People with Parkinson's disease with an Ashkenazi Jewish heritage.
The study has completed recruitment of healthy controls without the family history and ethnicity described above.
18 - 80
Healthy Volunteers Needed
Duration of Participation
For subjects found to carry a LRRK2, GBA or SNCA mutation who choose to participate in the full study, duration of participation will be approximately 3 years.
The Michael J. Fox Foundation for Parkinson's Research
There is no reimbursement (or cost to the participant) for the genetic testing portion of the study. Subjects subsequently participating in the full study will be paid $50 for completing each of the following visits: the Screening visit, the 3 month, 9 month, 18 month, and 30 month visit. Subject will be paid $200 for completing each of the following visits: the Baseline visit, the 6 month, 12 month, 24 month, and 36 month visit. If the subject chooses to leave the study early, s/he will only be compensated for the visits completed.